Genmab A/S ADS reported Q2 2026 revenue of $2.6B, a 25% increase, driven by Epkinley's 48% growth. Guidance revised to $4.3-4.5B for 2026.
Genmab A/S ADS reported Q2 2026 revenue of $2.6 billion (USD), marking a 25% increase year-over-year and surpassing the $2.5 billion consensus estimate. The significant revenue growth was primarily fueled by strong sales of Epkinley, which saw a remarkable 48% increase year-over-year, and the ongoing success of Darzalex.
Key Takeaways
- Revenue growth rose to $2.6 billion, up 25% year-over-year, reflecting strong portfolio performance.
- Epkinley sales reached $312 million for the first half of 2026, a 48% YoY increase, solidifying its position in the market.
- Darzalex revenue grew 21% YoY, contributing significantly to the overall sales performance.
- Updated guidance for 2026 includes revenue expectations of $4.3 to $4.5 billion, representing 19% growth at the midpoint, up from previous estimates of 14%.
- Operating profit is now projected between $1.1 billion to $1.4 billion, reflecting a 7% increase in profitability expectations.
Revenue Surge Driven by Key Assets
The latest financial results highlight a robust performance from Genmab's core products, particularly Epkinley and Darzalex. Revenue for the first half of 2026 totaled $1.7 billion, with Epkinley alone accounting for $312 million in sales, indicating a strong momentum in both the U.S. and international markets. Notably, the drug is gaining traction in community practices, with over 90% of key customers ordering for multiple sites, showcasing its growing acceptance among healthcare providers.
| Metric | Q2 2026 | YoY | QoQ |
|----------------|---------------|------------|------------|
| Revenue | $2.6B | +25% | N/A |
| Epkinley Sales | $312M | +48% | N/A |
| Darzalex Sales | N/A | +21% | N/A |
Management expressed confidence in Epkinley's potential, especially as it becomes a preferred treatment option for patients with diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). The anticipated launch of Epkinley in second-line FL later this year is expected to further bolster sales as it continues to gain regulatory approvals globally.
Strategic Guidance Signals Growth Ahead
Genmab has updated its 2026 financial guidance, reflecting increased expectations for both revenue and operating profit. The company now anticipates full-year revenue between $4.3 billion and $4.5 billion, a notable increase from earlier guidance of 14% growth. Operating expenses are expected to increase only 2%, demonstrating efficient capital allocation while maintaining investment in high-value growth opportunities, particularly in the expansion of Epkinley and the upcoming launch of Rena S and Pitocinab.
“The strength of our business and the financial flexibility it continues to create are reflected in our updated 2026 financial guidance,” said Anthony, CFO of Genmab.
Analyst Q&A Reveals Strategic Insights
During the analyst Q&A, multiple questions were raised regarding the timing and expectations for upcoming clinical trial readouts, particularly those related to the frontline trials of Epkinley and Rena S. Analysts pressed for clarity on the anticipated top-line results for the pivotal studies, which are expected to report in Q4 2026. Management reiterated their excitement about the data, particularly the Phase 3 trials, emphasizing that they are on track to deliver substantial updates in the coming months.
Frequently Asked Questions
Did Genmab A/S ADS beat earnings estimates in Q2 2026?
Yes, Genmab reported $2.6 billion in revenue, surpassing the consensus estimate of $2.5 billion by $100 million.
What is the expected revenue growth for Genmab in 2026?
Genmab now expects full-year revenue between $4.3 billion and $4.5 billion, indicating a 19% year-over-year increase at the midpoint.
How did Epkinley perform in Q2 2026?
Epkinley sales reached $312 million in the first half of 2026, representing a substantial 48% increase year-over-year.
What are the key drivers for Genmab’s updated guidance?
The updated guidance is primarily driven by the strong performance of Epkinley and Darzalex, alongside ongoing investments in new therapies and indications.
In conclusion, Genmab's impressive revenue growth and strategic guidance reflect the company's strong position in the oncology market. As the company prepares for significant trial readouts in the coming months, investors will be looking for continued momentum and clarity on the future trajectory of its key products.
This analysis is based on public earnings call materials and is not investment advice.
